Biomarkers of Extracellular Matrix Turnover

Bishop, 1995, Collagen turnover and its regulation in the normal and hypertrophying heart, Eur Heart J, 16, 38, 10.1093/eurheartj/16.suppl_C.38 Zannad, 2001, Treatment of congestive heart failure: interfering the aldosterone–cardiac extracellular matrix relationship, Hypertension, 38, 1227, 10.1161/hy1101.099484 D'Armiento, 2002, Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction, Trends Cardiovasc Med, 12, 97, 10.1016/S1050-1738(01)00160-8 Visse, 2003, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry, Circ Res, 92, 827, 10.1161/01.RES.0000070112.80711.3D Laviades, 1998, Abnormalities of the extracellular degradation of collagen type I in essential hypertension, Circulation, 98, 535, 10.1161/01.CIR.98.6.535 Weber, 1997, Monitoring tissue repair and fibrosis from a distance, Circulation, 96, 2488 Lopez, 2005, The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease, J Hypertens, 23, 1445, 10.1097/01.hjh.0000173780.67308.f1 Risteli, 1995, Analysing connective tissue metabolites in human serum. Biochemical, physiological, and methodological aspects, J Hepatol, 22, 77 Jensen, 1990, Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction, Circulation, 81, 52, 10.1161/01.CIR.81.1.52 Querejeta, 2000, Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease, Circulation, 101, 1729, 10.1161/01.CIR.101.14.1729 Querejeta, 2004, Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis, Circulation, 110, 1263, 10.1161/01.CIR.0000140973.60992.9A Diez, 2002, Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients, Circulation, 105, 2512, 10.1161/01.CIR.0000017264.66561.3D Hayashi, 2003, Circulation, 107, 2559, 10.1161/01.CIR.0000068340.96506.0F Izawa, 2005, Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study, Circulation, 112, 2940, 10.1161/CIRCULATIONAHA.105.571653 Lopez, 2006, Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure, J Am Coll Cardiol, 48, 89, 10.1016/j.jacc.2006.01.077 Lalu, 2005, Ischaemia–reperfusion injury activates matrix metalloproteinases in the human heart, Eur Heart J, 26, 27, 10.1093/eurheartj/ehi007 Inokubo, 2001, Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome, Am Heart J, 141, 211, 10.1067/mhj.2001.112238 Carver, 1991, Collagen expression in mechanically stimulated cardiac fibroblasts, Circ Res, 69, 116, 10.1161/01.RES.69.1.116 Mukherjee, 1990, Collagen phenotypes during development and regression of myocardial hypertrophy in spontaneously hypertensive rats, Circ Res, 67, 1474, 10.1161/01.RES.67.6.1474 Nakahara, 2007, Left ventricular hypertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type III amino-terminal peptide, Circ J, 71, 716, 10.1253/circj.71.716 Ahmed, 2006, Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease, Circulation, 113, 2089, 10.1161/CIRCULATIONAHA.105.573865 Martos, 2007, Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction, Circulation, 115, 888, 10.1161/CIRCULATIONAHA.106.638569 Lindsay, 2002, TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension, Hypertension, 40, 136, 10.1161/01.HYP.0000024573.17293.23 Muller-Brunotte, 2007, Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA), J Hypertens, 25, 1958, 10.1097/HJH.0b013e3282170ada Poulsen, 2005, Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension, Heart, 91, 624, 10.1136/hrt.2003.029702 Gonzalez-Vilchez, 2005, Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients, Int J Cardiol, 101, 53, 10.1016/j.ijcard.2004.03.009 Alla, 2006, Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes, Eur J Heart Fail, 8, 147, 10.1016/j.ejheart.2005.06.008 Berg, 1999, Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes, Diabetes Care, 22, 1186, 10.2337/diacare.22.7.1186 Quilliot, 2005, Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance, Int J Obes (Lond), 29, 1321, 10.1038/sj.ijo.0803022 Diez, 2007, Arterial stiffness and extracellular matrix, Adv Cardiol, 44, 76, 10.1159/000096722 Ishikawa, 2005, Collagen metabolism in extracellular matrix may be involved in arterial stiffness in older hypertensive patients with left ventricular hypertrophy, Hypertens Res, 28, 995, 10.1291/hypres.28.995 Kitahara, 2007, Serum carboxy-terminal telopeptide of type I collagen (ICTP) predicts cardiac events in chronic heart failure patients with preserved left ventricular systolic function, Circ J, 71, 929, 10.1253/circj.71.929 Jugdutt, 2003, Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?, Circulation, 108, 1395, 10.1161/01.CIR.0000085658.98621.49 Jugdutt, 2003, Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways, Curr Drug Targets Cardiovasc Haematol Disord, 3, 1, 10.2174/1568006033337276 Radauceanu, 2007, Residual stress ischaemia is associated with blood markers of myocardial structural remodeling, Eur J Heart Fail, 9, 370, 10.1016/j.ejheart.2006.09.010 Uusimaa, 1997, Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency, Circulation, 96, 2565, 10.1161/01.CIR.96.8.2565 Poulsen, 2000, Relationship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction, Circulation, 101, 1527, 10.1161/01.CIR.101.13.1527 Papadopoulos, 2005, Clinical significance of matrix metalloproteinases activity in acute myocardial infarction, Eur Cytokine Netw, 16, 152 Iraqi, 2009, Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the EPHESUS study, Circ J, 119, 2471, 10.1161/CIRCULATIONAHA.108.809194 Murakami, 1998, Clin Chem, 44, 2453, 10.1093/clinchem/44.12.2453 Cerisano, 2007, Relation between plasma brain natriuretic peptide, serum indexes of collagen type I turnover, and left ventricular remodeling after reperfused acute myocardial infarction, Am J Cardiol, 99, 651, 10.1016/j.amjcard.2006.09.114 Webb, 2006, Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling, Circulation, 114, 1020, 10.1161/CIRCULATIONAHA.105.600353 Mukherjee, 1991, Alteration of collagen phenotypes in ischemic cardiomyopathy, J Clin Invest, 88, 1141, 10.1172/JCI115414 Klappacher, 1995, Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis, Am J Cardiol, 75, 913, 10.1016/S0002-9149(99)80686-9 Zannad, 2000, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators, Circulation, 102, 2700, 10.1161/01.CIR.102.22.2700 Radauceanu, 2008, Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure, J Card Fail, 14, 467, 10.1016/j.cardfail.2008.02.014 Nishio, 2007, Cardiac troponin T vs other biochemical markers in patients with congestive heart failure, Circ J, 71, 631, 10.1253/circj.71.631 Rossi, 2007, Left atrial volume provides independent and incremental information compared with exercise tolerance parameters in patients with heart failure and left ventricular systolic dysfunction, Heart, 93, 1420, 10.1136/hrt.2006.101261 Bonapace, 2006, Aortic stiffness correlates with an increased extracellular matrix turnover in patients with dilated cardiomyopathy, Am Heart J, 152, e1 Everett, 2007, Atrial fibrosis and the mechanisms of atrial fibrillation, Heart Rhythm, 4, S24, 10.1016/j.hrthm.2006.12.040 Polyakova, 2008, Atrial extracellular matrix remodeling in patients with atrial fibrillation, J Cell Mol Med, 12, 189, 10.1111/j.1582-4934.2008.00219.x Kallergis, 2008, Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover, J Am Coll Cardiol, 52, 211, 10.1016/j.jacc.2008.03.045 Shimano, 2008, Circulating adiponectin levels in patients with atrial fibrillation, Circ J, 72, 1120, 10.1253/circj.72.1120 Tziakas, 2007, Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation, Europace, 9, 589, 10.1093/europace/eum072 Tziakas, 2007, Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension, Expert Opin Pharmacother, 8, 2225, 10.1517/14656566.8.14.2225 Blangy, 2007, Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction, Europace, 9, 724, 10.1093/europace/eum102 Ciulla, 2004, Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial, Circulation, 110, 552, 10.1161/01.CIR.0000137118.47943.5C Funder, 2006, Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects, Endocrinology, 147, 5564, 10.1210/en.2006-0826 Young, 2008, Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation, Curr Opin Nephrol Hypertens, 17, 174, 10.1097/MNH.0b013e3282f56854 Pitt, 2003, Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study, Circulation, 108, 1831, 10.1161/01.CIR.0000091405.00772.6E Sato, 2001, High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients, Hypertens Res, 24, 99, 10.1291/hypres.24.99 Zannad, 2005, Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure, Heart Fail Rev, 10, 71, 10.1007/s10741-005-2351-3 Majima, 2007, Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia, Endocrinol Jpn, 54, 145 Rajagopalan, 2007, Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension, Am J Cardiol, 100, 222, 10.1016/j.amjcard.2007.02.085 Zucker, 1999, Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications, Ann N Y Acad Sci, 878, 212, 10.1111/j.1749-6632.1999.tb07687.x Garnero, 2000, Ann Biol Clin (Paris), 58, 683 Fontaine, 2002, Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms, Am J Pathol, 161, 1701, 10.1016/S0002-9440(10)64447-1 Jung, 1996, Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood, Clin Chem, 42, 2043, 10.1093/clinchem/42.12.2043 Zucker, 2004, Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications, Adv Clin Chem, 38, 37, 10.1016/S0065-2423(04)38002-9 Cremers, 2006, Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls, Drugs, 66, 2031, 10.2165/00003495-200666160-00001